Recently, Changchun Bayi Hospital, Li Wanning et al studied telmisartan treatment of elderly patients with type 2 diabetes mellitus metabolic factors, the study found that, in addition to a better antihypertensive effect of telmisartan
, but also can improve glucose metabolism , Lipid metabolism and pancreatic islet function. For patients with hypertension and type 2 diabetes mellitus, especially in patients with metabolic syndrome has a good effect, can significantly improve their metabolic status. This article was published in the 2016 issue of "World's Newest Medical Information Digest."
The aim of this study was to investigate the effect of telmisartan on hypertension metabolic factors.
In the study, 78 patients with type 2 diabetes mellitus and hypertension were randomly divided into telmisartan and control group after two weeks of elution. The levels of blood glucose, insulin, glycosylated hemoglobin, lipids and high-sensitivity CRP were observed in two groups.
The results showed that telmisartan 2h postprandial blood glucose, plasma insulin, serum triglyceride, LDL, HbA1c significantly decreased compared with the control group, telmisartan had better antihypertensive effect, but also lower fasting blood glucose, High HDL, but little effect on high-sensitivity CRP.
Telmisartan is a new type of antihypertensive drugs, is a specific angiotensin Ⅱ receptor (AT Ⅰ type) antagonist for the treatment of essential hypertension. The alternative angiotensin II receptor binds with high affinity to the AT I receptor subtype, a known angiotensin II site. Telmisartan AT1 receptor site without any site agonist effect, selective binding with AT Ⅰ receptor, the binding lasting.